JIUYUAN GENE (02566) surged nearly 24% in late trading. As of press time, the stock was up 23.72% to HK$15.28, with a trading volume of HK$41.215 million.
On the news front, JIUYUAN GENE plans to hold a board meeting on August 18 (next Monday) to approve its interim results. Notably, as the company holds what could be China's first potential semaglutide biosimilar drug, metabolism has consistently been the most closely watched area for JIUYUAN GENE by the market.
Previously, at a results communication meeting on March 27, relevant executives from JIUYUAN GENE mentioned that the weight management indication is expected to submit for market approval in the first half of 2026. Regarding the market layout and channel planning for semaglutide, the company will strengthen its first-mover advantage in the hospital market, expand accessibility through pharmacy networks, collaborate strategically with e-commerce platforms, and accelerate brand building and user outreach.
Additionally, JIUYUAN GENE has licensed overseas rights for semaglutide to other domestic pharmaceutical companies: it signed an exclusive licensing cooperation agreement with Sinovac Biotech for semaglutide in major Latin American countries; it signed key terms of a product licensing agreement with Fosun Pharma, granting Fosun Pharma exclusive clinical development, registration, and commercialization rights for semaglutide and other products in the Middle East and North Africa, all sub-Saharan African countries, and some ASEAN countries.
The company is expected to submit new drug applications for semaglutide to Brazil and Saudi Arabia within 2025.
Comments